Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dyadic InternationalDYAI -1.87%39 3-Year EBITDA Growth Rate is 15.90% as of Mar. 2026. GuruFocus rates DYAI with a GF Score™ of 39/100 and a GF Value™ of $0.74 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,135 Biotechnology companies, Dyadic International ranks better than 51.28% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 15.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 16.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -8.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Dyadic International was 53.50% per year. The lowest was -124.30% per year. And the median was -6.90% per year.
Dyadic International (NAS:DYAI) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Dyadic International 3-Year EBITDA Growth Rate Related Terms
DYAI vs EXOZ, INMB, FLNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Dyadic International's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyadic International 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyadic International's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Dyadic International's 3-Year EBITDA Growth Rate falls into.
Dyadic International 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 15.90% mean?
Dyadic International (DYAI) has a 3-Year EBITDA Growth Rate of 15.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Dyadic International and its competitors. According to the industry distribution chart, Dyadic International ranks #553 out of 1135 companies in the Biotechnology industry, placing it in the top 48.7%.
Is Dyadic International's 3-Year EBITDA Growth Rate too high?
Dyadic International's current 3-Year EBITDA Growth Rate is 15.90%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Dyadic International's value of 15.90% is 6.7% above this industry median. Based on the distribution chart, Dyadic International ranks #553 out of 1135 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Dyadic International has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dyadic International's 3-Year EBITDA Growth Rate compare to EXOZ and INMB?
According to the Biotechnology industry distribution chart, Dyadic International ranks #553 out of 1135 companies for 3-Year EBITDA Growth Rate. This puts Dyadic International in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Dyadic International's value of 15.90% is 6.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dyadic International's current 3-Year EBITDA Growth Rate of 15.90% is 6.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Dyadic International and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dyadic International's current 3-Year EBITDA Growth Rate is 15.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyadic International stock overvalued right now?
Based on GuruFocus' analysis, Dyadic International (DYAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.74, compared to a current price of $1.06 — trading 42.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 15.90% and 6.7% above the Biotechnology industry median of 14.90. Dyadic International's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Dyadic International (DYAI), the current 3-Year EBITDA Growth Rate is 15.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dyadic International (DYAI) Overvalued in 2026?
Based on GuruFocus' analysis, Dyadic International stock appears to be overvalued.
The current stock price of $1.06 is trading 42.6% above its estimated GF Value™ of $0.74.
GuruFocus considers Dyadic International to be Significantly Overvalued.
Key valuation signals for DYAI:
3-Year EBITDA Growth Rate: 15.90%
GF Value™: $0.74 vs. price of $1.06 (42.6% above fair value)
Industry Position: 6.7% above the Biotechnology median (#553 of 1135)
No single metric tells the full story. See the DYAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
39GF Score
Get the complete analysis for DYAI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYAI has been successfully added to your 
